Highlights from the 2026 ASCO Genitourinary Cancer Symposium featuring key presentations in bladder, kidney, prostate, and rare cancers.
Tony Berberabe, MPH
Tony Berberabe, MPH, is the assistant managing editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey. He covers genitourinary cancers and myeloproliferative neoplasms. Contact him at aberberabe@targetedonc.com.
Articles by Tony Berberabe, MPH
The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.
The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer.
New ASCO Living Guidelines on prostate cancer emphasize first-line therapies, bone protection, and the growing role of genetic testing.
A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.
A recent white paper determines that the link between GLP-1 agonist inhibitors and thyroid cancer is unconvincing.
NPX372 received Investigational New Drug Clearance from the FDA, allowing for clinical development.
New research defines distinct therapeutic strategies for the 2 classes of CALR mutations in myelofibrosis, with implications for future patient management and clinical trial design.
Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.
During his presentation at the 4th Annual Miami Cancer Institute Precision Oncology Symposium, Petros Grivas, MD, PhD, FASCO, provided a detailed roadmap for community oncologists with an emphasis on precision medicine.
New research uncovers how genetic ancestry influences head and neck cancer biology, paving the way for personalized treatment strategies and improved patient outcomes.
A new clinical trial evaluates survival outcomes for recurrent head and neck cancer, comparing surgery with neoadjuvant chemotherapy and immunotherapy.
Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.
FDA designates OPN-2853 as an orphan drug for myelofibrosis, showing promising results in spleen size reduction and safety in clinical trials.
FDA fast-tracks BNT113, an mRNA immunotherapy, for treating HPV16+ head and neck cancer, enhancing immune responses alongside pembrolizumab.
Practice-changing 2025 breast cancer trial updates spotlight giredestrant, tucatinib maintenance, and ribociclib in key subtypes, boosting disease control with manageable safety.
The FDA reviews ropeginterferon alfa-2b-njft for essential thrombocythemia, showing promising efficacy in clinical trials for patients.
Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.
A novel ctDNA assay identifies high-risk triple-negative breast cancer patients post-surgery, highlighting its potential as a crucial prognostic tool.
XmAb819 shows promising antitumor activity and manageable safety in clear cell renal cell carcinoma patients, highlighting its potential in future therapies.
Immunotherapy shows significant survival benefits for metastatic chromophobe renal cell carcinoma patients with sarcomatoid features, suggesting a potential predictive biomarker.
New data from the SEQUOIA trial highlights the effectiveness of zanubrutinib and venetoclax in achieving high progression-free survival rates in CLL/SLL patients.
Lisaftoclax shows promising efficacy and safety in treating relapsed/refractory CLL/SLL, achieving a 62.5% response rate and 23.89 months progression-free survival.
New research from ESMO 2025 reveals significant survival benefits of intensified androgen blockade over traditional therapies for advanced prostate cancer.
A study reveals cabozantinib plus nivolumab shows a 71% response rate in fumarate hydratase-deficient renal cell carcinoma, promising survival outcomes.